Condition
Inherited Retinal Dystrophy Associated With RPE65 Mutations
Total Trials
2
Recruiting
0
Active
2
Completed
0
Key Insights
Highlights
Treatment Research
1 treatments under study, led by Lx101
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
Termination Rate
0.0%
0 terminated out of 2 trials
Late-Stage Pipeline
50%
1 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
2Total
Phase 1 (1)
Phase 3 (1)
Trial Status
Active Not Recruiting2
Clinical Trials (2)
Showing 2 of 2 trials
NCT06196827Phase 1Active Not RecruitingPrimary
Safety and Tolerability of LX101 for Inherited Retinal Dystrophy Associated With RPE65 Mutations
NCT07054632Phase 3Active Not RecruitingPrimary
Efficacy and Safety of LX101 for Inherited Retinal Dystrophy Associated With RPE65 Mutations
Showing all 2 trials
Research Network
Common Treatments
- Lx1012
Active Sponsors
- Innostellar Biotherapeutics Coltd2